Article Text

Download PDFPDF
Research news in clinical context
  1. Stefano Rusconi1,
  2. Kristine E Shields2,
  3. Ana Arias3,
  4. Sonia Raffe4,
  5. Marina Daskalopoulou5
  1. 1 DIBIC Luigi Sacco, University of Milan, Milan, Italy
  2. 2 Health Care Administration, Desales University, Center Valley, Pennsylvania, USA
  3. 3 Servicio de Ginecología Hospital Alemán and Sección Tracto Genital Inferior Hospital Carlos G Durand, Universidad de Buenos Aires, Buenos Aires, Argentina
  4. 4 University Hospitals Sussex NHS Foundation Trust, Worthing, UK
  5. 5 Institute for Global Health, University College London, London, UK
  1. Correspondence to Prof Stefano Rusconi, DIBIC Luigi Sacco, University of Milan, Milan, Italy; stefano.rusconi{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Treatment regimens for HIV or Hepatitis C Virus do not need to be altered during Paxlovid administration for COVID-19

Treatment with Paxlovid (nirmatrelvir/ritonavir 300/100 mg two times per day for 5 days) is expected to play an important role in patients with mild-to-moderate COVID-19 who are at risk of disease progression. Nirmatrelvir targets the SARS-CoV-2 3CL protease, whereas ritonavir acts as a pharmacological enhancer. Paxlovid is an inhibitor of CYP3A (Cytochrome P450, family 3, subfamily A) and may increase plasma concentrations of drugs that are primarily metabolised by CYP3A. Guidance has been released to indicate that people with HIV or hepatitis C virus who take Paxlovid can continue their antiviral treatment, including regimens containing ritonavir or cobicistat, without interruption or dose adjustments. With concomitant use, patients should be monitored for a potentially increased risk of adverse events. Other important interactions exist, including reduced Paxlovid therapeutic effect by drugs that induce CYP3A, that require careful management.1

Infectious Diseases Society of America and HIV Medicine Association. Paxlovid for the treatment of COVID-19: considerations for people with HIV and hepatitis C. December 31, 2021.

Published in Sexually Transmitted Infections: Depression is more common in MSM who report either sexual inactivity or condomless sex than in men who report condom-protected sex only

Studies on the association between depression and condomless sex have reported discordant findings. One possible explanation is that participants who report no recent sexual intercourse are merged with those who report condom-protected sex into a single ‘no condomless sex’ comparator group. Using data from two cross-sectional cohorts …

View Full Text


  • Handling editor Anna Maria Geretti

  • Twitter @drdaska

  • Contributors All authors contributed to the selection of articles and to the writing of summaries. SR submitted the final version to the journal.

  • Competing interests None declared.

  • Provenance and peer review Commissioned; internally peer reviewed.